Key result
Among hospitalized ovarian cancer patients, 65.25% experienced potential drug interactions, most commonly involving ondansetron/tramadol and metoclopramide/tramadol.
Why the study?
The study was conducted to identify the main therapeutic classes prescribed to ovarian cancer patients and evaluate potential drug interactions during hospitalization.
Population
236 hospitalized ovarian cancer patients at a referral gynecological cancer hospital in Brazil
Design
Descriptive retrospective study
Authors
Loading...
High prevalence of potential interactions in ovarian cancer inpatients supports pharmacist vigilance; hypothesis-generating for effects on outcomes.
Observational (n=236)
No
Hospitalized ovarian cancer patients face a high burden of potential drug interactions, highlighting the need for clinical pharmacist review to improve patient safety.
Badin et al. (2022) conducted an observational in ovarian cancer (n=236). Pharmacotherapy was evaluated on Potential drug interactions (PDI). Among hospitalized ovarian cancer patients, 65.25% experienced potential drug interactions, most commonly involving ondansetron/tramadol and metoclopramide/tramadol.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: